Evidence map›Paper›PMID 41684164›Full record

ArticleJournal of gynecologic oncology2026

Combined ER/PR co-positivity enhances prognostic stratification within molecular subtypes of endometrial cancer.

Ruxue Han, Yang Chen, Shuiqing Xu, Tingting Zhang, Xingran Jiang, Hua Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gynecologic oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruxue HanDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0009-0005-0577-7286
Yang ChenDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0009-0008-2684-737X
Shuiqing XuDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-3758-0446
Tingting ZhangDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0009-0009-0103-0889
Xingran JiangDepartment of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.ORCID https://orcid.org/0000-0002-3037-9205
Hua LiDepartment of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. hual_gyn@163.com.ORCID https://orcid.org/0000-0002-1172-6750

Funding

Clinical Research Incubation Project, Beijing Chao-Yang Hospital, Capital Medical University CYFH202306National Natural Science Foundation of China 62476180
6 · The paper itself

Abstract

objectiveTo explore the prognostic value of combined estrogen receptor (ER)/progesterone receptor (PR) expression patterns within molecular subtypes of endometrial cancer (EC), particularly in the prognostically heterogeneous no specific molecular profile (NSMP) subtype.

methodsA retrospective cohort study of 388 EC patients underwent next-generation sequencing-based molecular classification and ER/PR immunohistochemistry. ER/PR status was categorized as co-positive (coP), co-negative, or discordant. Multivariable Cox models and concordance index (C-index) analyses assessed disease-specific survival (DSS) and progression-free survival (PFS).

resultsER/PR co-positivity independently predicted improved DSS overall (hazard ratio [HR]=0.143; 95% confidence interval [CI]=0.065, 0.314; p<0.001) after adjusting for stage and molecular subtype. In NSMP (n=254), coP predicted superior DSS (HR=0.21; 95% CI=0.06, 0.87; p=0.034), while ER positivity predicted better PFS (HR=0.13; 95% CI=0.02, 0.88; p=0.037). Adding coP to staging improved NSMP-DSS prediction (ΔC-index=+0.082; p<0.05). No significant associations were found in non-NSMP subgroups.

conclusionER/PR co-positivity is a powerful independent predictor of favorable DSS in EC, particularly refining risk stratification for the NSMP subtype when integrated with molecular classification.

Indexed as

Endometrial NeoplasmsReceptors, EstrogenReceptors, ProgesteroneAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesBiomarkers, TumorReceptors, EstrogenReceptors, ProgesteroneEndometrial CancerEstrogen ReceptorMolecular ClassificationProgesterone ReceptorPrognosis

Identifiers

PMID41684164
PMCPMC13369452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.